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VII. 2.  In vivo Visualization of Tau Deposits in Corticobasal Syndrome 
by 18F-THK5351 PET 
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CBS is an asymmetric higher cortical dysfunction with parkinsonism, dystonia, and 
myoclonus1-4). 18F-THK5351 is a novel radiotracer with a binding affinity for tau protein 
deposits5). We did not know whether 18F-THK5351 radiotracers detect tau deposits in vivo 
in patients with CBS. We evaluated whether 18F-THK5351 PET can bind to tau pathology 
in living patients with CBS. 
Five patients with CBS and eight age-matched normal controls (NCs) underwent 
18F-THK5351 PET scans. Probable CBS was diagnosed based on the modified Cambridge 
criteria6). All patients were right-handed. The NC group was comprised of volunteers with 
no cognitive or motor function impairments, who did not have any observable 
cerebrovascular lesions as indicated by MRI scans. This study protocol was approved by 
the Ethics Committee of the Tohoku University Hospital. Written informed consent was 
obtained from each patient or his/her guardian(s) after they were given a complete 
description of the study. We performed image analysis using the PNEURO module in 
PMOD software (version 3.6). In statistical analysis, we used a repeated measures analysis 
of variance (ANOVA) followed by Holm-Sidak’s multiple comparisons test to compare 
regional 18F-THK5351 retention in normal controls versus patients with CBS. The analyses 
were performed using GraphPad Prism6 software.  
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18F-THK5351 PET images in a patient with CBS (70-year-old female, MMSE score 
13) and a NC (61-year-old female, MMSE score 30) are shown in figure 1. We observed 
high 18F-THK5351 retention in the precentral and postcentral gyri, and basal ganglia in the 
patient with CBS. 18F-THK5351 retention for the bilateral precentral, postcentral, superior 
frontal, and superior parietal gyri and globus pallidus and left posterior cingulate gyrus was 
significantly higher in patients with CBS than in NCs (p<0.005). In all patients with CBS, a 
higher uptake of 18F-THK5351 was seen in the regions contralateral to the 
symptom-predominant side. 
Higher accumulation of 18F-THK5351 was seen in the precentral and postcentral 
gyri, and globus pallidus in patients with CBS than in NCs. The spatial patterns of 
18F-THK5351 binding were compatible with tau deposit distributions observed in brain 
autopsies of patients with CBS7-9). These results suggest that 18F-THK5351 PET is able to 
visualize tau deposits in patients with CBS. One limitation in this study was the relatively 
small sample size. We therefore could not examine the association between 18F-THK5351 
retention and clinical severity in CBS. 
18F-THK5351 PET demonstrated high tracer signals in sites susceptible to tau 
deposition in patients with CBS. 18F-THK5351 should be considered as a clinical tool in the 
assessment of tau burden in CBS. Future clinical studies should clarify whether the 
radiotracer is a suitable biomarker for the early diagnosis and monitoring of disease 
progression in CBS1).  
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Figure 1.  18F-THK5351 PET images overlaid on MRI data in a patient with corticobasal syndrome (CBS) 
and in a normal control (NC) subject. 
18F-THK5351 retention in the precentral and postcentral gyri, globus pallidus, and putamen was more evident 
in the patient with CBS than in the NC. 
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